19 followers
Daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. https://t.co/89IDEqLKpZ
Daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. https://t.co/89IDEqLKpZ
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED… https://t.co/JteG4aXFWh